Kawasaki Disease Clinical Trial
Official title:
Rivaroxaban Versus Warfarin for Thromboprophylaxis in Children With Giant Coronary Artery Aneurysms After Kawasaki Disease: a Multicenter, Open-label, Parallel, Exploratory, Randomized Controlled Trial
Based on population pharmacokinetic model-based simulation, a 15 mg-equivalent, age-, and bodyweight-adjusted dosing regimen for Chinese children with giant coronary artery aneurysms after acute Kawasaki disease was proposed. This exploratory trial aims to evaluate the feasibility, safety and effectiveness of rivaroxaban compared to warfarin for thromboprophylaxis in children with giant coronary artery aneurysms after Kawasaki disease
Lifelong anticoagulant treatment is required in children with giant coronary artery aneurysm after Kawasaki disease, imposing social and psychologic burdens on patients and parents. Rivaroxaban is a potential oral anticoagulant in this population. Considering the impact of ethnic difference and growth development, we proposed a Chinese-specific, optimized dosing regimen based on model- and clinical evidence-informed precision dosing. This study is a multicenter, open-label, exploratory, randomized controlled trial to evaluate the feasibility, safety and effectiveness of rivaroxaban for thromboprophylaxis in Chinese children with giant coronary artery aneurysms after Kawasaki disease, following the 15 mg-equivalent, age-, and bodyweight-adjusted dosing regimen. Participants will be randomly assigned to the control or experimental groups. Randomization ratio will be 1:1. The control group will receive warfarin plus aspirin or clopidogrel, and the experimental group will receive Rivaroxaban plus aspirin or clopidogrel. Baseline characteristics, treatment effect outcomes, bleeding events, adverse events and compliance of intervention of each participant will be collected. Because this is an exploratory study and the low incidence of giant coronary artery aneurysm in children with Kawasaki disease, the study plans to recruit 100 participants. The aims include: - The feasibility - The safety and efficacy profile of the optimized, 15 mg-equivalent dosing regimen - The group differences in safety and treatment effect for antithromboprophylaxis between warfarin and rivaroxaban ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05911386 -
Multiparametric Echocardiography and Cardiac Biomarkers in Pediatric Inflammatory Heart Diseases
|
||
Recruiting |
NCT02951234 -
A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki Disease
|
N/A | |
Active, not recruiting |
NCT02853266 -
Measurement of Antibodies in Adults With a History of Kawasaki Disease
|
N/A | |
Active, not recruiting |
NCT04747847 -
Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease
|
Early Phase 1 | |
Withdrawn |
NCT04535518 -
Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease
|
Phase 3 | |
Recruiting |
NCT01917721 -
Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease
|
Phase 2 | |
Recruiting |
NCT04656184 -
A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment
|
Phase 3 | |
Recruiting |
NCT03200561 -
A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study)
|
Phase 3 | |
Completed |
NCT01440075 -
Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease
|
N/A | |
Completed |
NCT02179853 -
Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02980263 -
Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease
|
Phase 2 | |
Enrolling by invitation |
NCT02359643 -
Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease
|
N/A | |
Recruiting |
NCT04278404 -
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
|
||
Completed |
NCT00760435 -
Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease
|
Phase 3 | |
Completed |
NCT00841789 -
A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease
|
Phase 2 | |
Recruiting |
NCT02114099 -
Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease
|
Phase 2 | |
Not yet recruiting |
NCT05091229 -
A Blood Test to Diagnose Kawasaki Disease
|
||
Completed |
NCT01431105 -
Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities
|
Phase 1/Phase 2 | |
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Recruiting |
NCT06305611 -
European and North Indian Cohort of KaWasaki dIsease
|